대원제약

003220KOSPI의약품 제조업

41.1 / 100

Reference Date: 2026-07-24

Financial Score11.0 / 40

News Sentiment16.1 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is undervalued vs. peers but the high debt ratio poses financial risk. Slightly down 2.5% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Daewon Pharmaceutical operates in pharmaceuticals, cosmetics, and health functional foods, focusing on CMO services, overseas exports, and the development of OTC drugs and health supplements. Key subsidiaries include Daewon Meditech (hearing aid sales), Daewon Pharmaceutical Vietnam (Southeast Asia market expansion), SD Biotech (cosmetics brand 'SNP'), and 'Ogam Shikdak' (a 2022-launched convenience food brand targeting online markets with products like 'Token Broth').

Number of Employees

1,349people

Average Salary

77.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 11.234.0Point

PBR

0.63Industry Average 0.814.0Point

In line with industry avg

ROE

-1.44Industry Average 4.010.0Point

Well below industry avg

Debt Ratio

44.70Industry Average 12.430.0Point

3.6x industry avg (risky)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲7.4% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼50.1% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 3.7% (declining, 3yr)

Detailed News Sentiment

13 totalPositive 6Neutral 7Negative 0Average Sentiment Score 64.6

Neutral
삼성바이오에피스, 서울시와 차세대 신약기업 키운다
삼성바이오에피스와 서울시의 협력으로 바이오 신약 개발 기업 육성 프로그램이 시작되었으나, 직접적인 영향은 대원제약에 미치지 않는다.
Positive
[혁신형 제약기업 점검]⑨ 대원제약, 약가 특례 94억…권리 귀속 검증
대원제약이 혁신형 제약기업으로 인정받아 제네릭 약가 인하로 연간 94억원의 비용 절감 효과를 기대하며, 높은 R&D 투자 비율을 통해 지속 가능한 성장을 시사합니다.
Positive
대원제약 '대원헬스', 올리브영·홈쇼핑·대형마트 입점…옴니채널 강...
대원제약의 옴니채널 전략 확장으로 헬스케어 사업 성장 기대.

Detailed Momentum

52-week position1.0Point

Near 52w low (6%, downtrend)

Current 7,720Won52-week high 13,45052-week low 7,300

1-month return2.0Point

1m -2.53% (slight drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0